Circle Pharma Presents Preclinical Data on CID-078 at EORTC-NCI-AACR Symposium

Circle Pharma, a biopharmaceutical company based in South San Francisco, has announced that preclinical data for its leading drug candidate, CID-078, will be presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. This prestigious event, also referred to as the Triple Meeting, will be held in Barcelona, Spain, from October 23-25, 2024. CID-078 is an innovative oral macrocycle cyclin A/B RxL inhibitor and has shown promising results in preclinical trials.

The presentation, authored by Wang et al., is titled "CID-078, a First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers" and will be part of the late-breaking posters session. The abstract number for this presentation is PB-515, and the session will be held from October 23, 2024, at 6 a.m. EST / 12 p.m. CEST to October 25, 2024, at 11 a.m. EST / 5 p.m. CEST. Attendees of the symposium will be able to view the digital poster online.

The preclinical studies of CID-078 have shown notable single-agent tumor activity in various tumor cell lines and in vivo models characterized by dysregulated cell cycle (CDK-RB-E2F) function. Remarkably, tumor regressions were observed in models of small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). The effectiveness of CID-078 as a single agent was particularly associated with RB1 mutation, high E2F target scores, or G2M checkpoint hallmark pathway scores in specific cancer indications. These cumulative findings suggest that CID-078 has the potential to be an effective monotherapy for patients with these types of cancers. The drug is currently being evaluated in a multi-center phase 1 clinical trial (NCT06577987) that is actively enrolling patients.

CID-078 is an orally bioavailable macrocycle that inhibits cyclins A and B through RxL motif interference. This drug selectively targets tumor cells with oncogenic alterations leading to cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have demonstrated potent and selective disruption of the protein-to-protein interactions between cyclins A and B and their key substrates and modulators, including E2F and Myt1. The preclinical data has shown that these inhibitors can cause tumor regressions as a single agent in multiple in vivo models.

Circle Pharma, headquartered in South San Francisco, is a pioneering company focused on developing macrocycle therapies that can be administered through various routes, including oral delivery. The company employs its proprietary MXMO™ platform, which integrates structure-based rational drug design with advanced synthetic chemistry to create a new generation of macrocycle therapies aimed at challenging drug targets. Circle Pharma's primary focus is on cyclins, master regulators of cell cycle progression and critical drivers in numerous cancers.

The promising results from preclinical studies of CID-078 highlight Circle Pharma's potential to address unmet clinical needs in cancer treatment. As the company continues to advance its clinical trials, there is hope that CID-078 will offer a new therapeutic option for patients with cancers driven by dysregulated cell cycle mechanisms.